Abstract 562P
Background
Osi is a third-generation, CNS active EGFR-TKI. The primary analysis of the global, phase III, open-label, randomised FLAURA2 (NCT04035486) study in pts with EGFRm advanced NSCLC demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with 1L osi + chemotherapy (osi + CT) vs osi monotherapy (osi-mono). We report data of pts in China from FLAURA2.
Methods
Eligible pts (aged ≥18 yrs with locally advanced/metastatic EGFRm [Ex19del/L858R] NSCLC, WHO PS 0/1 and no prior systemic treatment [tx] for advanced NSCLC; stable CNS metastases allowed) were randomised 1:1 to osi + CT (osi 80 mg QD + pemetrexed [pem] 500 mg/m2 + either cisplatin 75 mg/m2 or carboplatin AUC5 Q3W for 4 cycles, followed by osi 80 mg QD + pem 500 mg/m2 Q3W) or osi-mono (80 mg QD) until progression/discontinuation criterion; stratified by race (Chinese Asian/non-Chinese Asian/non-Asian), EGFR mutation test method (local/central) and WHO PS (0/1). Primary endpoint: PFS by investigator assessment. Secondary endpoints included OS, ORR, DoR and safety. Data cut-off: 03 April 2023.
Results
Overall, 131 pts in China were randomised to osi + CT (n=67) or osi-mono (n=64). Baseline characteristics (osi + CT/osi-mono) were: median age (range), 61 (42–74)/60 (32–78) yrs; 63/59% female; 48/59% Ex19del; 51/39% L858R (1 unknown EGFR mutation type per arm); 51/42% CNS metastases. Osi + CT improved PFS vs osi-mono (49% maturity by investigator; Table). OS was immature (21% maturity); HR 0.97 (95% CI 0.45, 2.06). All grade ≥3 AEs (osi + CT/osi-mono): 75% (mainly haematological)/26%; AEs leading to osi discontinuation: 3/5%.
Conclusions
In the China cohort, osi + CT demonstrated a clinically meaningful improvement in PFS over osi-mono with a manageable safety/tolerability profile consistent with the global study population, supporting osi + platinum-pem as a new 1L tx option for pts in China with advanced EGFRm NSCLC. Table: 562P
Efficacy output | Osi + CT (n=67) | Osi-mono (n=64) |
Median PFS by investigator, months (95% CI) | 27.4 (22.3, NC) | 22.3 (16.7, 25.0) |
HR (95% CI) | 0.56 (0.34, 0.92) | |
Median follow-up for PFS, months (range)* | 22.3 (0–30.6) | 23.7 (3.0–33.1) |
Median PFS by BICR, months (95% CI) | 33.2 (25.1, NC) | 22.0 (16.6, NC) |
HR (95% CI) | 0.58 (0.34, 1.01) | |
Median follow-up for PFS, months (range)* | 24.2 (0–30.5) | 22.3 (3.0–33.2) |
ORR by investigator, n (%) | 58 (87) | 49 (77) |
Median DoR by investigator, months (95% CI) | 26.2 (20.7, NC) | 20.8 (15.3, 23.5) |
∗In censored pts.BICR, blinded independent central review; CI, confidence interval; DoR, duration of response; HR, hazard ratio; NC, not calculable; NR, not reached; ORR, objective response rate
Clinical trial identification
FLAURA2: NCT04035486.
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, Ph.D., of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
L. Jiang: Non-Financial Interests, Personal, Local PI: Shanghai Chest Hospital, Shanghai Jiao Tong University, PR China. J. Liu, Y. Liu: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. D. Kulkarni, X. Huang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. P.A. Jänne: Financial Interests, Personal, Advisory Board: AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyte, Takeda Oncology, Novartis, Voronoi, SFJ Pharmaceuticals, Biocartis, LOXO Oncology, PUMA, Sanofi, Transcenta, Daiichi Sa; Financial Interests, Personal, Other: Dr. Jänne is a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Oncology, PUMA, Astellas Pharmaceuticals, Daiichi Sankyo; Financial Interests, Personal, Royalties: Post marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp. All other authors have declared no conflicts of interest.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract